Pharmapack by Informa Markets, Europe’s leading event dedicated to pharmaceutical packaging and drug delivery, will return to Paris Expo Porte de Versailles on 21–22 January 2026. Celebrating its 25th anniversary, the event will bring together the global pharma, packaging and medical device ecosystem for two days of discussion, insight and technological exchange.
More than 6,000 participants from 90 countries are expected to attend, alongside 400 exhibitors and approximately 80 expert speakers. The programme reflects the growing strategic importance of packaging and delivery systems, not only as operational components, but as key contributors to patient experience, regulatory compliance and market access. Innovations in drug delivery systems, packaging design, medical devices and manufacturing processes will be at the centre of the exhibition and conference agenda.
The 2026 edition will focus on two major forces currently reshaping the industry: the rapid expansion of GLP-1 therapies and the increasing pressure to meet ambitious sustainability targets. From eco-design and new material solutions to the digitalisation of connected devices, the event will examine how pharmaceutical packaging must evolve to respond to these challenges while maintaining safety, performance and compliance.
“Pharmaceutical packaging and delivery systems are no longer just operational concerns; they are strategic levers for patient experience and market access,” said Sherma Ellis-Daal, Brand Director for Pharmapack by Informa Markets. “Pharmapack brings together the people and insights needed to solve real-world challenges and future-proof the supply chain.”
The content programme will address both global and practical issues facing the sector. A dedicated U.S.–Europe debate will explore how geopolitical shifts are affecting pharmaceutical packaging and supply chains, and how companies can respond at scale. Sustainability will be examined through an eco-design lens, with cross-industry lessons from cosmetics and pharma on reducing packaging volumes and material use without compromising product protection or regulatory requirements.
Digital transformation will also be a key theme. Sessions on artificial intelligence and regulatory intelligence will highlight how AI is enabling real-time data analysis and improved pharmacovigilance, while also addressing the governance and responsibility required to deploy such tools effectively. In parallel, the programme will take a critical look at connected care devices, assessing how pharmaceutical companies can regain momentum from consumer technology players in the field of wearables and connected health solutions for chronic disease management.
Through multiple conference tracks covering strategic, technical and regulatory topics, Pharmapack 2026 is designed to meet the needs of packaging engineers, R&D teams, regulatory specialists and commercial decision-makers. The aim is to provide concrete insights and forward-looking perspectives on the future of pharmaceutical packaging, medical devices and drug delivery technologies.
The event will be supported by six premium partners recognised for their role in advancing pharmaceutical packaging and delivery solutions: Aptar, Gerresheimer, SCHOTT Pharma, Stevanato Group, West and BD. These companies will play a central role in shaping the event’s content, exhibition presence and networking opportunities.
Innovation will also be celebrated through the Pharmapack Awards, which recognise excellence in sustainability, patient-centric design and technological innovation. For the 2026 edition, the awards will be sponsored by AAE B.V.
As the pharmaceutical industry faces increasing complexity and heightened expectations, Pharmapack 2026 positions itself as a key industry platform for sharing insight, fostering collaboration and shaping the future of pharmaceutical packaging and drug delivery. In its role as a media partner, The Pharmaceutical Post will follow the key announcements, trends and innovations emerging from Pharmapack 2026.